Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00773 ...
Drug Name Etoposide
Molecular Weight 588.5566
Molecular Formula C29H32O13
CAS Number 33419-42-0
SMILES [H][C@]12COC(=O)[C@]1([H])[C@H](C1=CC(OC)=C(O)C(OC)=C1)C1=CC3=C(OCO3)C=C1[C@H]2O[C@@H]1O[C@]2([H])CO[C@@H](C)O[C@@]2([H])[C@H](O)[C@H]1O
External Links
DRUGBANK DB00773
T3DB T3D4695
PubChem Compound 36462
PDR 1443
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 0.6 - 0.6 - HANSCH,C ET AL. (1995)
Melting Point 243.5 ℃ 236-251 ℃ PhysProp

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 50.0 % 50(25-75) % PO, oral; DRUGBANK
Bioavailability 52.0 % 52±17 % PO, oral; increasing doses ↓ ; The Pharmacological Basis of Therapeutics
C Max 2700.0 ng/ml 2.7 mcg/ml intravenous infusion, IV in drop; The Pharmacological Basis of Therapeutics
C Max 4700.0 ng/ml 4.7 mcg/ml intravenous infusion, IV in drop; hematological toxicity; The Pharmacological Basis of Therapeutics
T Max 1.3 h 1-1.5 h PO, oral; DRUGBANK
T Max 1.3 h 1.3 h The Pharmacological Basis of Therapeutics
Metabolic 40.0 % 40 % Urinary excretion; Unchanged drug; DRUGBANK
Clearance 2.4 L/h 33 - 48 ml/min Total clearance; intravenous injection, IV; adults; DRUGBANK
Clearance 0.51 L/h/m2 7.0-10 ml/min/m2 Renal clearance; DRUGBANK
Clearance 0.0408 L/h/kg 0.68±0.23 ml/min/kg hydrolysis; Children → ;Hepatic cirrhosis, cirr → ;RD, renal impairment, Renal disease，including uremia ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.0300 L/h/kg 0.5 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 23.5 L 18-29 L at steady state; DRUGBANK
Volume of Distribution 0.36 L/kg 0.36±0.15 L/kg Children → ;Hepatic cirrhosis, cirr → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.18 L/kg 0.18 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 7.5 h 4-11 h DRUGBANK
Half-life 8.1 h 8.1±4.3 h Children → ;RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr → ; The Pharmacological Basis of Therapeutics
Half-life 5.7 h 5.7 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Eliminate Route 44.0 % 44 % Faeces excretion; DRUGBANK
Eliminate Route 56.0 % 56 % Urinary excretion; DRUGBANK
Eliminate Route 35.0 % 35±5 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 97.0 % 97 % DRUGBANK
Protein Binding 96.0 % 96±0.4 % hypoalbuminemia Alb ↓ ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for infants 120.0 mg/m2/day 120 mg/m2/day intravenous injection, IV Toposar etoposide PDR
Max dose for children 150.0 mg/m2/day 150 mg/m2/day intravenous injection, IV Toposar etoposide PDR
Max dose for adolescents 200.0 mg/m2/day 200 mg/m2/day intravenous injection, IV Toposar etoposide PDR
Max dose for adults 200.0 mg/m2/day 200 mg/m2/day intravenous injection, IV Toposar etoposide PDR
Max dose for adults 100.0 mg/m2/day 100 mg/m2/day PO, oral Toposar etoposide PDR
Max dose for geriatric 200.0 mg/m2/day 200 mg/m2/day intravenous injection, IV Toposar etoposide PDR
Max dose for geriatric 100.0 mg/m2/day 100 mg/m2/day PO, oral Toposar etoposide PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1